Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

Abstract Background The therapeutic use of [131I]meta-iodobenzylguanidine ([131I]MIBG) is often accompanied by hematological toxicity, mainly consisting of persistent and severe thrombocytopenia. While MIBG accumulates in neuroblastoma cells via selective uptake by the norepinephrine transporter (NE...

Full description

Bibliographic Details
Main Authors: Thomas Blom, Rutger Meinsma, Marja Rutgers, Corine Buitenhuis, Marieke Dekken-Van den Burg, André B. P. van Kuilenburg, Godelieve A. M. Tytgat
Format: Article
Language:English
Published: SpringerOpen 2020-07-01
Series:EJNMMI Research
Subjects:
Meta-iodobenzylguanidine (MIBG)
Hematological toxicity
Thrombocytopenia
Platelets
Selective serotonin reuptake inhibitor (SSRI)
Online Access:http://link.springer.com/article/10.1186/s13550-020-00662-w

Internet

http://link.springer.com/article/10.1186/s13550-020-00662-w

Similar Items